MIRA Pharmaceuticals Completes Phase 1 Dosing for Ketamir-2 with Favorable Safety Profile

summarizeSummary

MIRA Pharmaceuticals announced the successful completion of Phase 1 dosing for its drug candidate Ketamir-2, reporting favorable safety and tolerability, and plans to advance to Phase 2a for chemotherapy-induced peripheral neuropathy.

check_boxKey Events

• Phase 1 Dosing Completed

  MIRA Pharmaceuticals has completed dosing in its Phase 1 clinical trial for Ketamir-2, involving 56 healthy adult volunteers across single and multiple ascending dose cohorts.

• Favorable Safety and Tolerability

  The study reported no serious adverse events or dose-limiting toxicities at any dose level. Crucially, no clinically significant dissociative or psychotomimetic effects typically associated with ketamine were observed.

• Advancing to Phase 2a for CIPN

  The company intends to submit documentation for a Phase 2a clinical study to the FDA in the first half of 2026. This study will target chemotherapy-induced peripheral neuropathy (CIPN), an indication with no currently FDA-approved therapies.

• Upcoming Data Presentation

  MIRA Pharmaceuticals plans to present the full Phase 1 data at an upcoming scientific meeting, providing further details on the drug's pharmacokinetics and safety.

auto_awesomeAnalysis

MIRA Pharmaceuticals has successfully completed Phase 1 dosing for its proprietary drug candidate, Ketamir-2, reporting no serious adverse events or dose-limiting toxicities. This positive safety and tolerability data is a crucial de-risking step for the company's pipeline, especially for a small biotech. The absence of typical ketamine-associated dissociative effects is a significant finding, potentially broadening the drug's therapeutic window. The company's plan to submit for a Phase 2a study in the first half of 2026, targeting chemotherapy-induced peripheral neuropathy (CIPN) which currently lacks FDA-approved therapies, highlights a substantial market opportunity. This positive development provides a counter-narrative to the recent insider stock sale reported on February 18, 2026, and could boost investor confidence in the company's drug development progress.